Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by the lack of expression of the dystrophin protein in muscle tissues. We genetically engineered a mouse model (mdx) of DMD that allowed for the high level and inducible transcription of a dystrophin mini-gene. This was achieved via the tetracycline-responsive transactivator (tTA) system. Multiple analyses confirmed that dystrophin expression in the mice was: (i) tTA dependent; (ii) correctly localized to the sarcolemmal membranes; (iii) capable of preventing the onset of dystrophy; and (iv) effectively blocked by the oral administration of tetracyclines. The model allowed us to somatically extinguish or induce dystrophin gene transcription. Somatic induction of dystrophin transcription prevented the onset of muscular dystrophy in some muscle groups. The levels of phenotypic rescue were influenced, however, by the age of the animals at the time of dystrophin induction. We also found that despite somatic termination of dystrophin gene transcription, the dystrophin protein was found to be associated with the sarcolemmal membrane for at least 26 weeks. Persistent detection of dystrophin was also accompanied by a prolonged protection of the muscle cells from the onset of dystrophy. The findings demonstrated that somatic transfer of the dystrophin gene not only may allow for the prevention of muscular dystrophy in multiple muscle groups, but also may be accompanied by persistent efficacy, secondary to the long-term functional stability of the dystrophin protein in vivo. This model should be useful in future studies concerning the potential of genetic therapy for DMD, as well as other muscle disorders.
INTRODUCTION
Duchene muscular dystrophy (DMD) is caused by a variety of mutations in the dystrophin gene, preventing the expression of a functional dystrophin protein (1) . The muscular dystrophy, X-linked mouse model (mdx), an animal model for DMD, has a point mutation in the murine dystrophin gene, fails to express significant amounts of murine dystrophin in muscle fibers and has been widely utilized to assess the potential of gene therapy to treat the human condition (2, 3) . Between 2 and 8 weeks after birth of the mice, most skeletal muscle fibers undergo at least one round of degeneration/regeneration, as assessed by the accumulation of muscle fibers containing centrally placed nuclei (4, 5) . Progressive involvement of the murine diaphragm (inflammatory and fatty infiltration, fibrosis) more closely resembles the degenerative changes observed in human patients with DMD (6) . As a result, significant decreases in the force and power generating capabilities of the mdx diaphragm have also been repeatedly demonstrated (6, 7) .
Previous studies have demonstrated that transgenic mdx mice constitutively expressing full-length or internally truncated forms of dystrophin (or utrophin) can be protected from muscle cell degeneration (7) (8) (9) (10) (11) . Each of these studies was limited, however, since the expression of the transgenes was initiated in utero, not somatically. Several attempts at virally mediated somatic transfer of mini-dystrophin or mini-utrophin genes into the skeletal muscles of neonatal mdx mice have further suggested that the prevention of dystrophic pathology can be accomplished (12) (13) (14) (15) (16) . However, the numerous limitations and/or side effects of the viral vectors utilized hindered these studies.
Due to the limitations of the above studies, key questions remain unanswered concerning gene therapy for DMD patients. For example, would expression of dystrophin in muscle cells be equally effective at earlier stages of disease progression as at later stages? Would the successful expression of dystrophin in a large number of muscle cells be accompanied by short-term benefits, or would clinical efficacy be expected to be demonstrable for longer durations? To begin to address these important questions, we have generated mdx mice that display inducible expression (or repression) of a murine dystrophin mini-gene in multiple muscle groups, at any point during the animal's lifespan, in a viral vector-independent manner.
RESULTS
It has previously been demonstrated that the utilization of a bicistronic gene induction system based upon the tetracycline resistance operon of Escherichia coli can be successfully utilized in transgenic animal models to allow for the inducible control of transgene expression (17, 18) . We wished to establish an animal model for DMD that allowed for the inducible control of dystrophin in multiple muscle groups of mdx mice, at any point during the animal's lifespan. In this manner, multiple questions regarding the potential of genetic therapies to treat DMD may be explored. We produced two strains of transgenic mice to accomplish this goal.
The first strain was transgenic for the MCK-tTA construct (tTA transactivator protein under the transcriptional control of the muscle creatine kinase promoter), whereas the second strain was transgenic for the ToDA construct (full-length murine dystrophin cDNA juxtaposed to the heptamerized tetoperator sequences that bind tTA). Founder animals (in a wildtype genetic background) were subsequently bred to either X mdx /Y male or X mdx /X mdx female mice and transgenic offspring were identified to contain the mdx allele as described in Materials and Methods. The breeding strategy resulted in the generation of ToDA/mdx or MCK-tTA/mdx lines of singly transgenic mice. Subsequently, the two strains of mice were inter-bred to generate mdx mice doubly transgenic for the ToDA and MCK-tTA transgenes, which we refer to as TODA+MCK-tTA/mdx mice. In this manner, the doubly transgenic animals would theoretically only express dystrophin in a tTA-dependent manner. Similarly, exposure of the doubly transgenic animals to tetracycline would theoretically allow for suppression of dystrophin expression, by inhibiting the binding of the tTA transactivator to the tet-operator motif flanking the dystrophin transgene (Fig. 1) .
TODA+MCK-tTA/mdx mice were assessed for tTAdependent expression of dystrophin by a number of parameters. Probing of the diaphragm, triceps, gastrocnemius and quadriceps muscle sections with dystrophin-specific antibodies confirmed that dystrophin was expressed and correctly localized to the sarcolemmal membranes of multiple muscle groups only in the TODA+MCK-tTA/mdx mice ( Fig. 2A) . Dystrophin expression appeared stable for periods of >52 weeks in a number of muscle groups ( Fig. 2A and data not shown) . The tTA dependence of dystrophin expression in TODA+MCK-tTA/mdx mice was also assessed (19, 20) . Immunofluorescent staining confirmed a lack of significant dystrophin expression both in ToDA/mdx mice and in TODA+MCK-tTA/mdx mice conceived and reared in the presence of tetracycline, for periods of >1 year ( Fig. 2A) . Whereas the quadriceps muscles displayed uniform patterns of dystrophin expression in the TODA+MCK-tTA/mdx mice, other muscle groups (triceps, gastrocnemius and diaphragm) showed variable (mosaic) levels of expression (data not shown). The mosaic expression of the dystrophin protein was unfortunately not able to be overcome despite the isolation, inter-breeding and screening of several independent MCK-tTA/mdx and ToDA/mdx lines of transgenic mice (data not shown).
Immunoblot detection of dystrophin in muscle extracts further confirmed that the levels of dystrophin expressed in TODA+MCK-tTA/mdx mice were comparable to the levels of dystrophin present in the muscles of wild-type mice (Fig. 2B) . The immunoblot also confirmed that treatment of TODA+MCK-tTA/mdx mice with tetracycline resulted in a near complete lack of expression of dystrophin. Immunoblot detection of dystrophin expression in transgenic mice. Equivalent amounts of protein derived from the quadriceps muscle were electrophoretically separated and transferred to nylon membranes and probed with a dystrophin-specific antibody (Dys-2). Note that the level of expression of dystrophin in ToDA+MCK-tTA/ mdx mice is nearly equivalent to the amount detected in wild-type mice and that tetracycline treatment of ToDA+MCK-tTA/mdx mice results in a lack of detectable dystrophin expression by this assay. wt, wild-type C57Bl/6 mouse; mdx, mdx mouse; Dt, ToDA+MCK-tTA/mdx mouse, 1 year old; Dt+tet, ToDA+MCK-tTA/mdx mice, maintained on tetracycline in utero until 52 weeks old. (C) Percentages of fibers containing central nuclei, quadriceps muscles of transgenic mice. Fibers containing central nuclei were assessed as described in Materials and Methods. Percentages that were significantly different (P < 0.02) than those noted in agematched mdx mice are denoted with an asterisk. n ≤ 3 for all ToDA+MCK-tTA/mdx mice (except at 1 year when n = 2), as well as for all mdx mice. nd, not determined.
As a quantitative measure of the morphological improvements in the muscle cells due to dystrophin expression, percentages of muscle fibers containing central nuclei (degenerated muscle fibers are typically replaced by muscle fibers containing centrally placed nuclei) were quantified and compared among the various mice (Fig. 2C) . The percentages of fibers containing central nuclei in the quadriceps muscles of the TODA+MCK-tTA/mdx mice were significantly decreased when compared with age-matched mdx mice, or age-matched ToDA/mdx mice. In contrast, the diaphragm muscles from the TODA+MCK-tTA/mdx animals failed to demonstrate significant differences in the percentage of fibers containing central nuclei, when compared with age-matched mdx mice, or ToDA/mdx mice (data not shown). The latter result was likely due to the more pronounced mosaic expression pattern of dystrophin in the diaphragm muscles of the TODA+MCK-tTA/mdx mice, as confirmed by probing of muscle sections with dystrophinspecific antibodies (8, 17) . Similar analysis of triceps and gastrocnemius muscles in TODA+MCK-tTA/mdx mice showed intermediate percentages of fibers containing central nuclei, relative to the percentages noted in the quadriceps and diaphragm muscles of ToDA/mdx and mdx mice. The overall mosaic level of expression also prevented us from noting significant differences in plasma creatine kinase levels among the various strains of mdx mice (data not shown).
With confirmation that dystrophin expression could be regulated via exogenous tetracycline treatment, we induced the somatic expression of dystrophin in ToDA+MCK-tTA/mdx mice at various times after their birth. Tetracycline inhibition (and dystrophin gene transcription initiation) was first relieved at the age of 2-4 days in TODA+MCK-tTA/mdx mice. Subsequent analysis of these mice at the age of 8 weeks demonstrated that the percentage of their muscle fibers containing centrally placed nuclei was significantly lower than those noted in the quadriceps and gastrocnemius muscles of age-matched mdx mice, but these levels were still significantly different from normal mice (Fig. 3 ). Significant amounts of sarcolemmaassociated dystrophin were also detected in the muscles of the somatically induced TODA+MCK-tTA/mdx animals using dystrophin-specific antibodies (data not shown).
Despite the significantly improved appearance of the quadriceps muscles, the percentage of muscle fibers containing central nuclei was significantly greater in ToDA+MCK-tTA/mdx mice somatically induced to express dystrophin, when compared with similar mice expressing dystrophin in utero. For example, in the quadriceps muscles of 8-week-old TODA+MCK-tTA/mdx mice that had been expressing dystrophin in utero, 28.6% of their muscle fibers (quadriceps muscle) contained central nuclei. In contrast, the quadriceps muscles of 8-week-old TODA+MCK-tTA/mdx mice induced to express dystrophin within 2-4 days of birth contained an average of 48.9% fibers with central nuclei, as compared with 71.7% of the fibers containing centrally placed nuclei in agematched mdx mice. Dystrophin expression induced at more advanced ages in TODA+MCK-tTA/mdx mice (either after 4-5 weeks of age, or after 30 weeks of age) did not significantly prevent, nor reverse, morphological evidence of dystrophy, based upon the percentage of muscle fibers containing central nuclei (P > 0.05; data not shown).
Next we determined how long dystrophin could maintain normal muscle morphology after termination of gene transcription. We were also interested in whether the results would be influenced by the temporal patterns of skeletal muscle degeneration previously described in mdx mice (5). Therefore, ToDA+MCK-tTA/mdx mice were administered oral tetracycline at different ages after birth to inhibit somatically tTAdependent dystrophin gene transcription. ToDA+MCK-tTA/mdx mice were administered oral tetracycline at either 5 weeks of age (early dystrophin shut-down), which is during the first few waves of muscle degeneration, or after 8 weeks of age (late dystrophin shut down) when most muscle fibers have undergone at least one round of degeneration.
RT-PCR analysis of dystrophin mRNA transcripts isolated from the quadriceps muscles of the tetracycline-treated TODA+MCK-tTA/mdx mice confirmed a lack of tet-operatorderived dystrophin RNA transcription during tetracycline treatments, a result consistent with previous in vivo studies (Fig. 4) (17, 19, 20) . Despite the lack of transcription, in situ dystrophin-specific antibody probing of muscle sections derived from the 'late dystrophin shut down' group of mice demonstrated widespread detection of sarcolemma-associated dystrophin, despite 26 weeks of abated gene transcription (Fig. 5) . Additionally, the percentage of muscle fibers containing central nuclei in this group of mice 22 weeks after dystrophin expression termination was not significantly different than those noted in ToDA+MCK-tTA/mdx mice whose dystrophin transcription had either (i) never been terminated or (ii) only been terminated for 4 weeks (Fig. 6A) . However, 26 weeks after termination of dystrophin gene transcription a significant increase in the percentage of fibers containing central nuclei was observed in this group of mice (Fig. 6A) . Concordant with these results, immunofluorescent detection of dystrophin in the sarcolemmal membranes was also waning, but still evident 26 weeks after termination of gene transcription (Fig. 5) .
Interestingly, inhibition of dystrophin transcription in the early dystrophin shut down group of TODA+MCK-tTA/mdx mice led to an earlier onset of dystrophic changes, based upon the percentages of muscle fibers containing central nuclei ( Fig. 6B) . For example, 4 weeks after tetracycline was administered to this group of TODA+MCK-tTA/mdx mice, the percentage of quadricep muscle fibers containing central nuclei were not significantly different than the central nuclei percentages noted in non-tetracycline-treated TODA+MCK-tTA/mdx mice (Fig. 6B ). However, a significant increase in the number of fibers containing central nuclei was noted in the early dystrophin shut down TODA+MCK-tTA/mdx mice as early as 6 weeks after tetracycline inhibition of dystrophin transcription had been initiated (Fig. 6B) . We also noted that in the latter group of experimental animals, dystrophin expression was significantly decreased, but still detectable, based upon indirect immunofluorescent detection of the respective muscle sections.
DISCUSSION
DMD is a progressive, degenerative muscle disease which is currently being evaluated as a promising target for potential gene therapy strategies. Utilization of the mdx mouse model of DMD has allowed a number of insights to be gained into the potential of gene therapy to treat humans with DMD. We have attempted to improve the utility of this mouse model by generating a strain of mdx mouse that allows for the expression of dystrophin to be inducibly controlled, at any point throughout the mouse's lifetime, simply by administering oral tetracycline to the animals. Importantly, the inducible expression of dystrophin was facilitated by the use of the tetracycline responsive-transactivating system as originally described by Gossen et al. (18) .
Our results demonstrated that expression of dystrophin was dependent on the presence of the MCK-tTA transgene, in TODA+MCK-tTA/mdx mice and that tTA-dependent dystrophin expression could be sustained in multiple muscle groups for periods of >1 year. The dystrophin protein RNA isolated from individual mice was subjected to RT-PCR with either dystrophin-or GAPDH-specific primers as described in Materials and Methods. A, mdx mouse; B, wild-type mouse; C, ToDA/mdx mouse; D, MCKtTA+ToDA/mdx; E and F, MCK-tTA+ToDA/mdx mice exposed to tetracycline since conception (intra-uterine) for 29 or 52 weeks, respectively; G and H, MCK-tTA+ToDA/mdx mice initially exposed to tetracycline somatically, for either 4 or 6 weeks, respectively. Note that all ToDA+MCK-tTA/mdx mice that were somatically exposed to tetracycline for >6 weeks were also similarly negative for any evidence of dystrophin gene transcription (data not shown). expressed with this system was also correctly localized to the sarcolemmal membranes of all muscle tissues tested, although expression was non-uniform in several tissues (most acute in the diaphragm muscles) based upon in situ indirect immunofluorescent detection of dystrophin. The non-uniformity of expression of dystrophin in the TODA+MCK-tTA/mdx mice also correlated with overall muscle morphology. For example, sufficient and uniform amounts of dystrophin expression in the quadriceps muscles of TODA+MCK-tTA/mdx mice resulted in significantly improved quadriceps muscle histology, when compared with the quadriceps muscles of age-matched mdx, or ToDA/mdx mice.
Importantly, the expression of dystrophin could also be prevented in TODA+MCK-tTA/mdx mice for periods of >1 year by tetracycline-mediated inhibition of the tTA protein, even when initiated in utero. Finally, at intermittent time points, the withdrawal or addition of tetracycline also effectively resulted in the somatic induction or cessation of dystrophin gene transcription in the TODA+MCK-tTA/mdx mice.
Experiments utilizing this system demonstrated that the expression of dystrophin significantly improved the muscular pathology noted in mdx animals. In utero expression, however, resulted in a more dramatic improvement in muscle morphology, in contrast to induction of dystrophin expression within the first few days after birth. The latter results, however, did correlate with previous somatic gene transfer experiments involving the direct injection of adenovirus vectors carrying mini-dystrophin transgenes into neonatal animals (14, 21) . We also did not note any abatement in the onset of the dystrophic process (as assessed by the percentage of muscle fibers containing central nuclei) when dystrophin gene expression was initiated just after the age of 4 weeks. However, at this age, mdx mice already have significant numbers of muscle fibers containing central nuclei, therefore differences between inducibly expressing dystrophin mice and mdx mice would be more difficult to validate.
Similarly, dystrophin gene expression was induced in older animals, but no obvious changes in muscle cell morphology were noted. It must be emphasized, however, that these studies were primarily based upon the assessment of muscle fibers containing central nuclei in various muscle groups. Significant changes in central nuclei counts in adult TODA+MCK-tTA/ mdx mice (as compared with mdx mice) would have required the reversal of existing morphological features of muscular dystrophy, i.e. conversion of muscle cells from those containing central nuclei to those with peripherally placed nuclei. Perhaps investigation at later time points, or the investigation of other indicators of muscle pathology (force and power generating capabilities, permeability of muscle membranes to dyes, such as Evans blue) may reveal further positive impacts of somatic dystrophin expression in older mdx mice.
We also demonstrated that the abatement of dystrophin transcription in adult TODA+MCK-tTA/mdx mice could be achieved by the somatic administration of tetracycline. Despite prolonged inhibition of dystrophin transcription (>26 weeks) in situ immunofluorescent staining continued to demonstrate that significant amounts of the dystrophin protein persisted on the sarcolemmal membranes of the treated mice. Importantly, this result correlated with prevention of the onset of muscular dystrophy symptoms (presence of high numbers of muscle fibers containing central nuclei) during the same time period. The results suggested that the dystrophin protein may be an especially hearty protein, since the functional abilities of sarcolemma-associated dystrophin to prevent muscle fiber degeneration in vivo exceeded 6 months. Although we could not detect any-ToDA-derived gene transcription (as assessed by RT-PCR) we cannot entirely rule out what role extremely low level, tetoperator-derived dystrophin gene transcription (coupled with a relatively low turn-over rate) may have had on the observed results.
These results also suggest that currently envisioned gene transfer strategies for DMD have a higher likelihood of success. For example, it has been demonstrated recently that first generation adenovirus-based vectors can persist in the muscles of immune-competent animals for long periods of time, but that gene transcription derived from the persistent vector genomes gradually wanes (22) . Our results suggest that (B) Percentage of fibers containing central nuclei in quadriceps muscles after early dystrophin shut-down. MCK-tTA+ToDA/mdx mice were treated with tetracycline for the indicated periods of time prior to being 6-weeks-old. For both figures, the number of fibers containing central nuclei were assessed as described in Materials and Methods. Percentage of fibers containing centrally placed nuclei that were significantly different (P < 0.05) than those noted in age matched mdx mice are denoted with an asterisk. dt, MCK-tTA+ToDA/mdx mice, off, period of time that dystrophin transcription was prevented by tetracycline mediated inhibition of dystrophin transcription. Note that n ≤ 3 for all experimental groups, except the dt-off 4 week group of animals (n = 2) in Figure 6A , resulting in P = 0.06. in such scenarios previously expressed dystrophin protein may be capable of functionally protecting the muscle cells for an additional 6 months after transcriptional down-regulation of the persistent vector occurs. Furthermore, our results suggest that the frequency of vector re-administration necessary for treating DMD patients may be significantly reduced because of the extended time periods that sarcolemma-associated dystrophin can both persist and prevent the onset of muscle fiber degeneration. We note that all viral vectors elicit potent neutralizing antibody responses that prevent vector re-administration. A diminished frequency requirement for the administration of dystrophin-encoding vectors will lessen this concern. These observations, combined with recent advancements in overall adenovirus vector technology, or recent attempts at inducing dystrophin expression via aminoglycoside-induced 'exonskipping' strategies, suggests that a single gene therapy treatment of DMD patients may allow for a 'long-term' functional protection of muscle cells, once significant amounts of dystrophin protein expression have been successfully initiated (23) .
We also noted that the abatement of dystrophin transcription in younger TODA+MCK-tTA/mdx mice (5-week-old) resulted in a more rapid onset of dystrophy than that noted in similar experiments with older TODA+MCK-tTA/mdx mice. These results suggest (but do not prove) that sustained production of dystrophin is more critical in younger, growing muscles, than in older muscles. Future studies are required, however, before this observation can be more fully understood. The utilization of TODA+MCK-tTA/mdx mice expressing larger amounts of the dystrophin protein may allow for greater levels and/or a more prolonged protection at younger ages than noted with the current strain of TODA+MCK-tTA/mdx mouse utilized in this study.
Several significant limitations of the inducible-dystrophin/ mdx mouse model were also noted. For example, of seven MCK-tTA/mdx lines isolated and evaluated by our group, only one provided adequate levels of tTA to allow for the high levels of dystrophin expression achieved in this study. Furthermore, we isolated and screened four lines of mdx mice transgenic for the ToDA transgene, but only one was capable of being transactivated by tTA co-expression. Interestingly, this line also had the highest copy number of ToDA transgenes integrated (based upon quantititive analysis of transgene copy number; data not shown) a result suggesting that the responsiveness of tet-operator linked gene sequences to tTA-mediated trans-activation may be influenced by the immediate chromatin structure flanking the tet-operator transgene construct. Large tandem arrays of the ToDA transgene may have insulated the transgene from the mouse chromatin, allowing for improved access of the tTA protein to the tetoperator motif.
We also noted that despite the use of a strong musclespecific promoter, we have yet to isolate a TODA+MCK-tTA/ mdx line of mouse capable of expressing enough dystrophin to consistently achieve 100% correction of all the variously affected muscle cells noted in the mdx mouse. This is in contrast to our previous studies utilizing mice transgenically expressing dystrophin directly from the MCK enhancer/ promoter, some of which expressed up to 50-fold greater amounts of dystrophin than that noted in wild-type mice (7, 8) . Paralleling these observations, we also noted a significant amount of mosaic dystrophin expression in ToDA+MCK-tTA/mdx animals (both within the various muscle groups of individual mice, as well as between transgenic littermates) a problem that diminished the statistical significance of some of our experimental observations. This was likely due to the inherent difficulties commonly associated with transgene expression in murine muscle cells. For example, it has been documented previously that mosaic expression of transgenes in muscle tissues can limit the usefulness of such models, a phenomenon also referred to as a 'position-effect' or variegation of transgene expression (8, 17) . The utilization of bi-cistronic gene transcription systems (such as the tet-operator/tTA transactivator system) likely exacerbates these variables, as noted by our studies, as well as by others utilizing the same systems in transgenic animals (17) . Possibly, the utilization of tTA-dependent systems based upon monogenic tTA-based constructs may alleviate this problem: unfortunately tTA-independent, low level expression of the respective tet-operator linked genes may also prevent these systems from allowing for tightly regulated control of transgene expression (24) .
MATERIALS AND METHODS

Transgene construction
To adapt the tetracycline-responsive transactivating system for both muscle specific use, as well as for temporal regulation of dystrophin expression in vivo, we constructed two transgenes (Fig. 1) . The first transgene was constructed by directional subcloning of the muscle creatine kinase (MCK) enhancer, promoter and first intron elements [6.5 kb fragment (7)] directly upstream of the tTA coding sequences and polyadenylation signals (EcoRI-NarI subfragment of pUHD15-1, kindly provided by Dr H. Bujard) (18) . This strategy generated the bacterial plasmid containing the transgene we refer to as MCK-tTA.
The second transgene was constructed by subcloning the XhoI-EcoRI subfragment of pUHD10-3 [containing the heptamerized tetracyline operator motif and minimal cytomegalovirus (CMV) promoter sequence (tet-operator)] into the XhoI and EcoRI sites of pBSX + polyA (7) to generate pToA (18) . Next, an ∼14 kb EagI DNA subfragment containing the full-length murine dystrophin cDNA (7) was subcloned into EagI-digested pToA resulting in the construction of the bacterial plasmid pToDA. This subcloning strategy placed the tet-operator sequences upstream and an SV-40 polyadenylation signal downstream, of the dystrophin cDNA.
Confirmation as to the integrity of the transgene constructs was verified by multiple restriction enzyme digests (data not shown). Prior to microinjection, the MCK-tTA transgene sequences were released and purified away from bacterially derived plasmid sequences via KpnI and PacI digestion, while the ToDA transgene sequences were released as a BssHII subfragment.
Isolation and identification of transgenic mdx mice
The two transgenes were delivered to the University of Michigan or Duke University Microinjection/Transgenic core facilities for production of transgenic mice, as previously described (7) . Each transgene was independently injected into fertilized hybrid embryos to prevent the possibility of tandem co-integration and possible loss of tTA-dependent transcription of the tet-operator-linked dystrophin gene. Genomic DNA isolated from mice potentially transgenic for the MCK-tTA transgene was digested with EcoRI, electrophoretically separated, transferred to a nitrocellulose-based membrane and probed with a 32 P-labeled 1.1 kb DNA fragment containing the tTA sequences derived from digestion of pUHD-15-1 with EcoRI and BamHI. Tail DNA isolated from mice potentially transgenic for the ToDA gene mice was similarly evaluated by probing with a 32 P-labeled 1.9 kb EcoRI subfragment (spanning nucleotides 11 853-13 836) of the murine dystrophin cDNA. The membranes were exposed to autoradiographic film and mice containing the respective transgenes were identified by visual comparison with appropriate control samples. All founder animals (wild-type) were subsequently bred with either X mdx /Y or X mdx / X mdx mice (C57BL-10), to isolate each transgene as a singly transgenic breeding line on an mdx background (i.e. ToDA/ mdx or MCK-tTA/mdx mice). Transgenic offspring from these breedings were identified as mdx by use of a previously described mdx-ARMS (amplification refractory mutation system) assay, or by the X-linked inheritance pattern of the mdx allele (25) . Finally, ToDA/mdx animals were crossed to MCK-tTA/mdx animals, to generate ToDA+MCK-tTA/mdx doubly transgenic offspring.
It was necessary to individually inter-cross seven lines of the singly transgenic MCK-tTA/mdx mice with four lines of the singly transgenic ToDA/mdx mice, before a suitable transgenic combination was found that allowed for the highest levels of tTA-dependent dystrophin expression in a variety of muscle tissues. All subsequent results in TODA+MCK-tTA/mdx mice were therefore based upon the use of the single most optimal MCK-tTA/mdx and ToDA/mdx lines, as determined from these initial screenings.
Indirect dystrophin immunofluorescence
Animals were sacrificed at the time points indicated in the figures. Muscle sections were placed in cryosectioning medium and snap frozen in liquid nitrogen cooled isopentane. Seven micrometer cryosections were rinsed in potassiumphosphate-buffered saline with 0.2% gelatin (KPBSG) and probed with a murine monoclonal antibody directed against the central rod domain of dystophin (MANDYS8) (Sigma, St Louis, MO) or with a rabbit polyclonal antibody, directed against the N-terminal domain of dystrophin (26) . The sections were then probed with a goat (anti-mouse or anti-rabbit) biotin-labeled secondary antibody, followed by exposure to fluorescein isothiocyanate-conjugated streptavidin and DAPI staining of nuclei. Visualization of muscle cells was performed with a fluorescent-photographic microscope (Leica DMBL, Wetzlar, Germany). All images were recorded using identical photographic parameters with a Spot digital camera and software package, at 100× magnification.
Muscle fibre cell central nuclei assessments
Muscle sections were fixed overnight in PBS containing 3.5% formaldehyde and 0.5% glutaraldehyde, rinsed and embedded in paraffin. Two to three micrometer thick cross-sections were obtained, mounted onto glass slides and stained with hematoxylin and eosin. The sections were assessed for percentage of fibers containing central nuclei. On average, 1000 fibers were counted per section, or in the case of the diaphragm, all muscle fibers in the cross-section were evaluated. Representative sections were photographed and recorded with the Spot digital camera and software package. The percentage of fibers containing central nuclei derived from each of the experimental groups were statistically compared (P-value determinations) utilizing a Student's t-test.
Tetracycline administration
Designated animals received tetracycline at a dose of 1.0 mg/ml in their drinking water. Females were administered tetracycline continuously, prior to mating, when in utero, tetracycline exposure of transgenic offspring was desired.
RT-PCR
Muscle sections were obtained and RNA isolated as previously described (27) . Muscle RNA (2 µg) was digested with DNaseIfor 15 min at room temperature and the reaction stopped with the addition of EDTA to 25 mM and heating for 10 min at 65°C. Complimentary DNA was generated from DNaseItreated RNA by the addition of 20 ng of random primers (Gibco BRL, Rockville, MD) and SuperScript reverse transcriptase (RT) (Gibco BRL) in vendor-supplied RT buffer (Gibco BRL) at 42°C for 1 h. DNA derived from the reactions was subjected to PCR amplification (Taq polymerase; Gibco BRL) in vendor-supplied PCR buffer (Gibco BRL) utilizing primers that spanned nucleotides 10 278-10 960 (exons 69-75) of the murine dystrophin cDNA, 5′-GCACTCCGACTA-CATCCGGAGAAGA-3′ (forward); and 5′-CCTTCTGGTG-TTATTTGTCGACCTC-3′ (reverse) (PCR product of 680 bp). As an internal control for ensuring adequate RNA isolation and amplification, a second RT-PCR reaction was repeated on all samples, specific for sequences present in the murine GAPDH gene, 5′-ACCACAGTCCATGCCATCAC-3′ (forward) and 5′-TCCACCACCCTGTTGCTGTA-3′ (reverse) (PCR product ∼350 bp). PCR denaturation, annealing and amplification parameters were as previously described (25) . Reaction products derived from the PCR reactions were electrophoretically separated in a 1% agarose gel and visualized with ethidium bromide staining. To confirm that the DNaseI treatment of the RNA samples was complete, all samples demonstrating evidence of dystrophin expression were similarly assayed, but without addition of reverse transcriptase: no PCR products with either dystrophin-or GAPDH-specific primer pairs were generated in these control experiments (data not shown). The sensitivity of the RT-PCR reaction was also confirmed: RNA derived from mdx mice was DNAseI treated and reverse transcribed and subsequently spiked with decreasing amounts of the pToDA plasmid (from 3000 to 3 molecules of the pToDA plasmid per reaction). PCR of these control samples with the dystrophin-specific primer pairs detected the dystrophinencoding DNA throughout the experimental range (data not shown).
Immunoblot detection of dytstrophin
Animals were sacrificed at indicated time points, portions of quadriceps muscles were snap frozen in liquid nitrogen, homogenized, resuspended in extraction buffer and insoluble protein removed by centrifugation as previously described (8) . Soluble muscle protein (200 µg) was electrophoretically separated in a 6% SDS-PAGE gel, electro-transferred to a nylon membrane, probed with the Dys-2 (Novocastra, Newcastle, UK) monoclonal antibody and visualized with the ECL (Amersham Pharmacia, Buckinghamshire, UK) detection kit, as previously described (28) .
